SureTrader SureTrader SureTrader
Home > Boards > US Listed > Biotechs >

Tracon Pharmaceuticals, Inc. (TCON)

TCON RSS Feed
Add TCON Price Alert      Hide Sticky   Hide Intro
Moderator: DewDiligence
Search This Board:
Last Post: 1/9/2017 11:07:31 AM - Followers: 5 - Board type: Free - Posts Today: 0

TRACON Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, age-related macular degeneration and fibrotic diseases. We are a leader in the field of endoglin biology and are using our expertise to develop antibodies that bind to the endoglin receptor. Our lead product candidate, TRC105, is an anti-endoglin antibody that is being developed for the treatment of multiple solid tumor types in combination with inhibitors of the VEGF pathway. Our other product candidates are TRC205, an anti-endoglin antibody that is in preclinical development for the treatment of fibrotic diseases, and TRC102, a small molecule that is in clinical development for the treatment of lung cancer and glioblastoma. Each of our product candidates is expected to complement currently available therapies.
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
TCON
Current Price
Volume:
Bid Ask Day's Range
SureTrader
TCON News: Current Report Filing (8-k) 01/09/2017 06:05:42 AM
TCON News: Current Report Filing (8-k) 01/03/2017 05:04:51 PM
TCON News: Current Report Filing (8-k) 12/21/2016 06:04:59 AM
TCON News: Current Report Filing (8-k) 12/13/2016 05:11:28 PM
TCON News: Amended Statement of Beneficial Ownership (sc 13d/a) 12/08/2016 11:26:43 AM